Hopefully they are using a PD-1 inhibitor in that study and are checking both PD-1 and PDL-1 expression. Leronlimab in combo will of course outperform just a PD-1 or PD-L1 on it's own. But if it's a PD-1 inhibitor and they're checking for PDL-1 expression they'll see the PD-1 inhibitor adds very little to leronlimab. If they use a PD-L1 inhibitor they may not notice that leronlimab also reduces PD-L1.

I knew leronlimab reduced PDL-1 but by how much was an unknown. When this paper was released then I knew.

https://jitc.bmj.com/content/8/1/e000228